tbuckley/cabot-search huggingface dataset:
AB0559 PATIENTS WITH EARLY-ONSET SJÖGREN’S SYNDROME
Authors: R. Caetano Ataides, O. H. Bentivoglio de Menezes Pereira, V. Barbosa
Journal: Annals of the Rheumatic Diseases (2022)

Background The primary Sjögrens Syndrome (pSS) is an autoimmune systemic disease characterized by chronic inflammation of exocrine glands, especially lacrimal and salivary glands. The onset of pSS is usually between 50 and 60 years of age, but it may also occur in younger patients, in which case may be associated with a worse progression of the disease and a worse prognosis. Objectives To describe the clinical and immunological profile of patients with primary SS, aiming to investigate the clinical and laboratory characteristics of early-onset pSS patients (diagnosis before 35 years old) Methods The data of 58 medical records were analysed retrospectively. Based on the disease onset age, the patients were divided into two groups those with the onset age of 35 years old or younger and those with the onset age of older than 35 years old. Data normality was verified with the Shapiro-Wilk test. The comparison between patients’ profiles with the late and early diagnosis was done with Pearson’s Chi-squared test, Student’s t-test, and Mann-Whitney test. P &lt;0.05 was considered statistically significant. Results 55 patients were female (94,8%) and 3 were male (5,2%) and the average age on the last medical visit was 45,91±12,46 years old and the time between the diagnosis and the last appointment (follow up time) was 56,90±61,57 months. 14 patients had early-onset pSS and 44 had late-onset pSS. The mean diagnosis age in the early-onset group and the late-onset group. was 30,21±4,21 vs 50,91±9,73 years old (p&lt;0.001) respectively and a mean follow-up time was of 41,40±50,27 vs 61,75±64,64 months respectively. There was no significant difference in demographic profile between the two studied groups, except for the age. There was no significant difference in cutaneous, joint, renal, and nervous system involvement. However there was a significantly higher frequency of xerophthalmia in the late-onset group (88.6% vs 64.3% p=0.036) and a significantly higher frequency of parotid enlargement in the early diagnosis group (42.9% vs 20.5% p=0.036) There was no significant difference in laboratory profiles between the two groups (anti-Ro, anti-La, ANA, rheumatoid factor, hypergammaglobulinemia and low complement). Conclusion The profile clinical of early-onset pSS patients may be different to those with later onset, with a higher prevalence of parotid enlargement. This group of patients needs to be monitored to determine the risk of a worse prognosis. References [1]ANQUETIL, C. et al. Is early-onset primary Sjögren’s syndrome a worse prognosis form of the disease? Rheumatology (United Kingdom), v. 58, n. 7, p. 1163–1167, 2019. [2]YAYLA, M.E., KARAMAN, Z., TORGUTALP, M. et. al. Early onset primary Sjögren syndrome, clinical and laboratory characteristics. Clinical Rheumatology, v. 39, p. 2689-2696, 2020. Disclosure of Interests None declared
Epidemiology, Management, and Outcomes of Sepsis in ICUs among Countries of Differing National Wealth across Asia
Authors: Andrew Li, Lowell Ling, Hanyu Qin, Yaseen M. Arabi, Sheila Nainan Myatra, Moritoki Egi, Je Hyeong Kim, Mohd Basri Mat Nor, Do Ngoc Son, Wen-Feng Fang, Bambang Wahyuprajitno, Madiha Hashmi, Mohammad Omar Faruq, Boonsong Patjanasoontorn, Maher Jaffer Al Bahrani, Babu Raja Shrestha, Ujma Shrestha, Khalid Mahmood Khan Nafees, Kyi Kyi Sann, Jose Emmanuel M. Palo, Naranpurev Mendsaikhan, Aidos Konkayev, Khamsay Detleuxay, Yiong Huak Chan, Bin Du, Jigeeshu Vasishtha Divatia, Younsuck Koh, Charles D. Gomersall, Jason Phua
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Directly comparative data on sepsis epidemiology and sepsis bundle implementation in countries of differing national wealth remain sparse.
AB0486 INFLAMMATORY MUSCULOSKELETAL ABNORMALITIES BY CONTRAST ENHANCED MRI IN SLE PATIENTS
Authors: P. Corzo Garcia, I. Garcia-Duitama, A. Agustí Claramunt, I. Carrión Barberà, S. Marsico, J. Monfort, T. C. Salman Monte
Journal: Annals of the Rheumatic Diseases (2022)

Background Joint involvement in SLE is the most frequent manifestation and shows a wide heterogeneity 1 . It has not a valid classification and it is often underestimated. Subclinical inflammatory musculoskeletal involvement is not well known 2 . Objectives We aim to describe the prevalence of joint and tendon involvement in hand and wrist of SLE patients, either with clinical arthritis, arthralgia or asymptomatic and compare it with healthy subjects using contrasted MRI. Methods SLE patients fulfilling SLICC criteria were recruited and classified as follows: group (G) 1: hand/wrist arthritis, G2: hand/wrist arthralgia, G3: no hand/wrist symptoms. Jaccoud arthropathy, CCPa and RF positivity, hand OA or surgery were excluded. Healthy subjects (HS) were recruited as controls: G4. Contrasted MRI of non-dominant hand/wrist was performed. Images were evaluated following RAMRIS criteria extended to PIP, Tenosynovitis score for RA and peritendonitis from PsAMRIS. Groups were statistically compared. Results 107 subjects were recruited (G1: 31, G2:31, G3:21, G4:24). Any lesion: SLE patients 74.7%, HS 41.67%; p 0.002. Synovitis: G1: 64.52%, G2: 51.61%, G3: 45%, G4: 20.83%; p 0.013. Erosions: G1: 29.03%; G2: 54.84%, G3: 47.62%; G4: 25%; p 0.066. Bone marrow edema: G1: 29.03%, G2: 22.58%, G3: 19.05%, G4: 0.0%; p 0.046. Tenosynovitis: G1: 38.71%; G2: 25.81%, G3: 14.29%, G4: 0.0%; p 0.005. Peritendonitis: G1: 12.90%; G2: 3.23%, G3: 0.0%, G: 0.0%; p 0.07. Conclusion SLE patients have a high prevalence of inflammatory musculoskeletal alterations by contrasted MRI, even if asymptomatic. Not only tenosynovitis but peritendonitis is also present. References [1]Ceccarelli F et al. Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment. Semin Arthritis Rheum. 2017;47:53-64 [2]Di Matteo A et al. Imaging of Joint and Soft Tissue Involvement in Systemic Lupus Erythematosus. Curr Rheumatol Rep. 2021;23:73 Acknowledgements This work has been granted by GSK and Societat Catalana de Reumatologia and we want to acknowledge them for their collaboration Disclosure of Interests PATRICIA CORZO GARCIA Grant/research support from: GSK, Ivan Garcia-Duitama: None declared, Anna Agustí Claramunt: None declared, Irene Carrión Barberà: None declared, Salvatore Marsico: None declared, Jordi Monfort Grant/research support from: GSK, Tarek Carlos Salman Monte Grant/research support from: GSK
POS0484 LUNG ORGANOIDS: A NOVEL APPROACH TO STUDY THE MOLECULAR PATHOLOGY OF PULMONARY FIBROSIS IN SYSTEMIC SCLEROSIS
Authors: M. Aspari, S. R. Greisen, K. Soendergaard, M. N. Dahl, M. Hvid, V. Ong, D. Abraham, B. Deleuran
Journal: Annals of the Rheumatic Diseases (2022)

Background Pulmonary fibrosis is one of the major manifestations in Systemic Sclerosis (SSc) associated with high mortality. Mesenchymal transformation of the airway epithelial cells has been implicated as one of the causes for developing pulmonary fibrosis. Though several animal models shed light towards some of these aspects, an in vitro airway epithelial model would provide a novel experimental platform for the understanding and molecular and genetic changes that occur in SSc associated pulmonary fibrosis. Objectives To establish a functional model for airway epithelium from patient with diffuse cutaneous SSc (dSSc)and healthy volunteers derived nasal stem cells. Subsequently to induce Epithelial Mesenchymal transformation (EMT). Methods Nasal stem cells harvested from healthy volunteers(HV) and dSSc patients were differentiated into ciliated airway epithelium in an Air -Liquid Interface (ALI) using a transwell system. 4 HV cultures were then stimulated with TGF beta (5ug/ml) for 10 days at a basal stage and when differentiated. Markers of mesenchymal transformation including loss of E cadherin, and gain of N cadherin, fibronectin and vimentin were analysed by flow cytometry and image stream, and mean expression intensities given as (MFI). Secreted Type 1 collagen and fibronectin were measured by ELISA. Results Ciliated epithelial cultures could successfully be established from nasal stem cells (Figure 1). TGF beta induced a phenotypic change in the epithelial cells towards a mesenchymal one in HV cultures. This was observed by significantly increased expression of fibronectin and vimentin and loss of expression of E cadherin on the ciliated cells with 7 days of stimulation with TGF beta at a basal stage (Figure 1b). When cells, stimulated with TGF beta for 7 days, were analysed at Day 35 a similar trend was seen in their Delta MFI (Figure 1c). Stimulating the ALI cultures with TGF beta for 20 days completely repressed epithelial cell growth and disrupted their microstructure. Figure 1. Conclusion This novel ALI differentiated Airway epithelial model serves as a functional organoid to test various pulmonary manifestations of Systemic Sclerosis. The ability to induce Epithelial Mesenchymal Transformation of these cultures provides a proof of concept for TGF beta mediated fibrosis in dSSc. Moreover, this model can be utilized to explore, at the cell and molecular level, the impact of various autoantibodies and therapeutics on epithelial cells. References [1]Mehmet Kesimer,1 Sara Kirkham,2 Raymond J. Pickles,3 Ashley G. Henderson,4 Neil E. Alexis,5 Genevieve DeMaria,1 David Knight,2 David J. Thornton,2 and John K. Sheehan1 Tracheobronchial air-liquid interface cell culture: a model for innate mucosal defense of the upper airways?; Am J Physiol Lung Cell Mol Physiol 296: L92–L100, 2009 Disclosure of Interests None declared.
AB0932 Patient and learner experience in a new set up of a rheum-derm combined care model for psoriatic arthritis
Authors: C. Hong, L. Fang, Y. W. Yeo, H. Y. Lee, A. Low, Y. Y. Leung
Journal: Annals of the Rheumatic Diseases (2022)

Background Psoriasis (PsO) and musculoskeletal manifestations are common among patients with psoriatic arthritis (PsA). A shared-care model between rheumatologists and dermatologists has been advocated to promote early diagnosis and improve management care. Data from Asia is scanty. Patients’ and learners’ experience of shared-care models are seldom explored. Objectives We described the set-up of a new shared-cared PsA-PsO clinic incorporating service, education and research between rheumatologist and dermatologist for PsA. We describe the patients’ and learners’ experience of this shared-care model. Methods A combined care clinic was newly set up in 2019. Referrals were internal through either specialty. Each patient was first seen by a trainee, followed by both a dermatologist and rheumatologist simultaneously in the same consultation room. We collected patients’ and learners’ experience through self-administered survey. Results From May 2019 to January 2020, data from 44 visits (55% new referrals, 45% follow-up) from 28 patients were captured in the PsA-PsO clinic. 50% of cases were referred from either specialty. 34% were referred for diagnostic doubts, 66% were for therapeutic issues. 61% of patients continued follow-up in the PsA-PsO clinic, and 39% discharged back to respective care. From patients’ experience rated on scale from 0-10, median (interquartile range, IQR) rating of the care was 8 (7, 8). 69.2% and 96% of patients would recommend the care to others. Free text comments included enhanced convenience, time saving, and having both specialties input on management. From 20 learners (3 medial students, 12 residents, 4 senior residents and one scientist), 95% reported extremely or very beneficial to training, 77.8% reported improved confidence in care for PsA and/or PsO patients. The PsA-PsO clinic was temporally suspended during the Covid-19 viral pandemic since February 2020 due to lack of manpower and not fulfilling the spacing out requirement for infectious control. The service was resumed gradually from May 2021. Conclusion Despite challenges, we report the setup of a new care model between dermatologists and rheumatologists for care of patients with psoriatic disease. The care model was well received by patients. Learners from various levels reported benefit from the learning experience. Disclosure of Interests Cassandra Hong: None declared, Liwen Fang: None declared, Yi-Wei Yeo: None declared, Haur Yueh Lee: None declared, Andrea Low: None declared, Ying Ying Leung Speakers bureau: Received honorarium from Abbvie, DKSH, Janssen, Novartis and Pfizer.
Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection
Authors: Antonio G. Dias, Caroline Atyeo, Carolin Loos, Magelda Montoya, Vicky Roy, Sandra Bos, Parnal Narvekar, Tulika Singh, Leah C. Katzelnick, Guillermina Kuan, Douglas A. Lauffenburger, Angel Balmaseda, Galit Alter, Eva Harris
Journal: Science Translational Medicine (2022)

Preexisting cross-reactive antibodies have been implicated in both protection and pathogenesis during subsequent infections with different dengue virus (DENV) serotypes (DENV1-4). Nonetheless, humoral immune correlates and mechanisms of protection have remained elusive. Using a systems serology approach to evaluate humoral responses, we profiled plasma collected before inapparent or symptomatic secondary DENV3 infection from our pediatric cohort in Nicaragua. Children protected from symptomatic infections had more anti-envelope (E) and anti–nonstructural protein 1 (NS1) total immunoglobulin G (IgG), IgG4, and greater Fc effector functions than those with symptoms. Fc effector functions were also associated with protection from hemorrhagic manifestations in the pre-symptomatic group. Furthermore, in vitro virological assays using these plasma samples revealed that protection mediated by antibody-dependent complement deposition was associated with both lysis of virions and DENV-infected cells. These data suggest that E- and NS1-specific Fc functions may serve as correlates of protection, which can be potentially applied toward the design and evaluation of dengue vaccines.
AB1493 REHABILITATION OF PATIENTS WITH ОSTEOARTHRITIS OF THE KNEE USING MAGNETIC THERAPY
Authors: A. Arkhipova, N. Zhuravleva, E. Guryanova, V. Diomidova
Journal: Annals of the Rheumatic Diseases (2022)

Background Currently, along with the basic treatment at the outpatient stage of rehabilitation, methods using physical and balneological factors are successfully applied: magnetotherapy, electrotherapy, peloidtherapy. Objectives Evaluation of the effectiveness of rehabilitation using magnetotherapy for osteoarthritis of the knee joints at the second radiological stage. Methods The study included 75 patients with primary osteoarthritis of the knee joints of the II X-ray stage, who were on outpatient rehabilitation in the sanatorium “Chuvashiyakurort”, including 45 women and 30 men aged 50 to 65 years with a disease duration of 15 to 20 years. Rehabilitation was carried out by a multiprofessional team led by a physical and rehabilitation doctor. All patients were divided into two groups by simple randomization. The main group (n = 50) received basic treatment (chondroprotectors) + non-steroidal anti-inflammatory drugs (NSAIDs on demand) and a course of apparatus magnetotherapy. Magnetic therapy was applied to the area of the knee joints using the «Polus-2» apparatus using solenoid inductors, mode - continuous, frequency - 50 Hz, low-sinusoidal current, intensity 111-1V, procedure duration 20 minutes, daily, № = 10. The control group (n = 25) received basic treatment (chondroprotectors) and NSAIDs (on demand). When analyzing the results of treatment, the VAS and WOMAC scales were used, and the Bartel index was estimated. Results In both groups, from the 2nd week of treatment, there was a decrease in pain during movement and at rest according to the VAS data compared with the baseline level. In patients in the main group, there was a decrease in joint swelling, a decrease in the level of pain according to the VAS by 41.3% (p &lt;0.05). The range of motion in the joints increased by 19.5% (p &lt;0.05) in the study group. In the control group, a decrease in the level of pain by 20.1% (p &lt;0.05) was recorded, the range of motion in the joints did not change. The overall WOMAC index was also lower in the main group compared with the control group (p = 0.03). Patients in the main group differed from patients in the control group in a significantly higher degree of dependence in daily life (Bartel index) and a lower score on the battery of tests of physical functioning. According to the results of dynamic observation of patients, no side effects associated with the use of the device “Polyus-2” were registered. Conclusion Magnetic therapy relieves pain, improves motor and daily activity in patients with osteoarthritis of the knee joints and can be recommended for use in medical rehabilitation programs in addition to basic therapy. References [1]Use of therapeutic preformed and physical factors in sanatorium conditions in the Сhuvash Republic // Methodical recommendations / Cheboksary, 2021. 60 p. Disclosure of Interests None declared
POS0745 GUT DYSBIOSIS ASSOCIATED WITH PERIPHERAL LYMPHOCYTES AND CYTOKINES IN PATIENTS WITH SJÖGREN’S SYNDROME
Authors: S. Song, S. X. Zhang, J. Qiao, R. Zhao, T. Cheng, X. Li
Journal: Annals of the Rheumatic Diseases (2022)

Background Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by disorders of lymphocyte subpopulations with various cytokines and auto-antibodies 1 . Growing evidences suggest that gut microbiome dysbiosis may contribute to the development of pSS 2 . Objectives To investigate the alterations to the gut microbiome and the correlation with peripheral lymphocytes and serum cytokines as well as inflammatory factors in pSS patients. Methods A total of 101 pSS patients and 101 age- and sex- matched healthy controls (HCs) were enrolled in this study from The Second Hospital of Shanxi Medical University (Taiyuan, Shanxi, China). Patients fulfilled the 2019 ACR/EULAR classification criteria. We conducted 16S rRNA gene sequencing using fecal microbiota samples and analyzed the peripheral lymphocyte subsets by flow cytometry. Serum cytokines, erythrocyte sedimentation rate (ESR), C-reaction protein (CRP), unstimulated and stimulated whole saliva (UWS and SWS) secretion rate was also collected, respectively. Sequence data were compiled and processed using Qiime2 and OTU-profiling tables were constructed. Correlations between different taxa and gut microbiome, as well as clinical variables, were calculated by Spearman’s rank test. Results Patients with pSS exhibited a significant reduction in the richness and diversity of gut microbiota compared with those of HCs (Figure 1A-B, p &lt; 0.05). Detailly, at the phylum level, pSS patients had a lower frequency of Firmicutes while higher Proteobacteria (Figure 1C, p &lt; 0.05). Compared with HCs, 11 species of flora were discovered to be distinctly different at the genus level (p &lt; 0.05). Patients presented fewer Faecalibacterium and Roseburia but more Lactobacillus (Figure 1D, p &lt; 0.05). Lactobacillus negatively correlated with T cells (r=-0.407), CD8+T (r=-0.417) and Th2 (r=-0.323). There was a significant positive correlation between Faecalibacterium and IL-2(r=0.312), IFN-γ(r=0.338), TNF-α levels(r=0.322) (Figure 1E, p &lt; 0.05). As for clinical disease measures, IL-6 increases were in line with ESR and CRP, while IL-2 levels inversely related to CRP. Additional UWS secretion rate and SWS secretion rate had negative correlation with ESR (Figure 1F, p &lt; 0.05). Conclusion The structural disorder of gut microbiota was distinct in pSS which were associated with peripheral lymphocyte subsets and cytokines. Disorders of gut microbiota and immune systems may contribute to the occurrence and development of pSS. References [1]Mariette X, Criswell LA. Primary Sjogren’s Syndrome. N Engl J Med 2018;378(10):931-39. doi: 10.1056/NEJMcp1702514 [2]Trujillo-Vargas CM, Schaefer L, Alam J, et al. The gut-eye-lacrimal gland-microbiome axis in Sjogren Syndrome. Ocul Surf 2020;18(2):335-44. doi: 10.1016/j.jtos.2019.10.006 Acknowledgements This work was supported by the National Natural Science Foundation of China (No. 82001740). Disclosure of Interests None declared
AB1085 COVID-19 VACCINATION INTENTION AMONG TUNISIAN HEALTH CARE WORKERS
Authors: O. Hamdi, M. Boudokhane, Z. Teyeb, I. Abdelaali, T. Jomni, S. Belakhal, M. H. Dogui
Journal: Annals of the Rheumatic Diseases (2022)

Background Health care workers (HCW) are the soldiers in the forefront of the fight against the coronavirus (COVID-19) pandemic. It is therefore a priority target group in the COVID-19 vaccination process. Objectives Our purpose was to assess the COVID-19 vaccination intentions of Tunisian HCW and the reason for fear in case of hesitancy. Methods We conducted an anonymous online questionnaire in the months of May and June 2021among HCW via social networks. The data collected included demographic characteristics, vaccination intentions, and reasons of hesitancy. Results Five- hundred HCW were included in the study. Participants were divided as follows: 74% doctors (15% seniors, 37% juniors, 22% interns), and 26% nurses. The mean age was 34 ± 5 years [24 – 58]. Seventy-three percent of participants were female. A history of chronic illness was noted 150 HCW (30%). A psychiatric disease was noted in 105 participants (21%): anxiety disorder (62%), depression (33%), and bipolar disorder (5%). A treatment was prescribed in 63% of cases: anxiolytics (84.2%), antidepressants (16.6%), and neuroleptics (10%). Psychotherapy was prescribed in 47% of cases. A personal and family history of COVID-19 infection was noted in 50.4 and 55% of cases, respectively. The infection was mild in 91.2% of cases. Four-hundred and five HCW (81%) had the intention to get vaccinated against COVID-19. Twenty participants (4%) refused the vaccine, and 75 (15%) were still hesitant. Vaccination hesitancy was linked to concerns about the safety of a rapidly-developed vaccine in 92% of cases: adverse reactions (95.8%), tolerance (75%), and efficacy (25%). Sixteen percent of hesitant respondents expressed concerns about the involvement of policy in vaccine development. Vaccines to avoid according to participants were: Astra Zeneca (62%), Synovac (26%), Sputnik (8%), and Pfizer (4%). Conclusion The intention to be vaccinated against COVID-19 reached 81% among Tunisian HCW. Acceptance of the vaccine, even among medically informed individuals, is based on a personal perception of the risks and benefits of vaccine safety. Hence the need for campaigns targeting both the general population and the HCW. Disclosure of Interests None declared